Allogene: If MRD Holds, This Becomes A Completely Different Company

petri dish reports

7/08/202603:34

Allogene Therapeutics maintains a $423.6M cash balance, disciplined cost controls, and a runway into 2029. Read why I rate ALLO stock a Buy.